Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Trading at a discount near its net cash on balance sheet plus the value of its approved therapy Casgevy. The market's expectations...
— Brent Jackson
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on CRISPR Therapeutics
No other institutional pitches found for this ticker yet.
More institutional theses from Orbis Global Equity Fund
Motorola Solutions ($MSI) represents approximately 3% of the strategy and serves as a premier provider of mission-critical public safety infrastructure and emergency communications technology. The company specializes...
Following its recent demerger from Unilever, the business now trades publicly as a standalone company.